Table 1 Baseline characteristics of patients by heart rate recovery (HRR) on exercise treadmill testing (n = 8236)
| Â | Impaired HRR n = 2425 | Normal HRR n = 5811 | P value |
|---|---|---|---|
Demographics | Â | Â | Â |
Age, median (25th, 75th percentiles), y | 63 (54, 70) | 54 (47, 63) | < 0.0001 |
Male, No. (%) | 1199 (49.4) | 3113 (53.6) | < 0.001 |
ETT indications | Â | Â | < 0.0001 |
Chest pain | 451 (18.6) | 984 (16.9) | Â |
Atypical chest pain | 920 (37.9) | 2953 (50.8) | Â |
Risk stratification | 200 (8.3) | 354 (6.1) | Â |
Screening | 272 (11.2) | 580 (10.0) | Â |
Other | 582 (24.0) | 940 (16.2) | Â |
Clinical History | Â | Â | Â |
Hypertension, No. (%) | 1552 (64) | 2487 (42.8) | < 0.0001 |
Diabetes Mellitus, No. (%) | 546 (22.5) | 619 (10.7) | < 0.0001 |
Lipid disease, No. (%) | 1677 (69.2) | 3611 (62.1) | < 0.0001 |
Current or recent smoking, No. (%) | 393 (16.2) | 741 (12.8) | < 0.0001 |
Obese (BMI > = 30), No. (%) | 1026 (42.3) | 1736 (29.9) | < 0.0001 |
Coronary artery disease, No. (%) | 450 (18.6) | 629 (10.8) | < 0.0001 |
Congestive heart failure, No. (%) | 74 (3.1) | 43 (0.7) | < 0.0001 |
COPD, No. (%) | 237 (9.8) | 145 (2.5) | < 0.0001 |
Mitral valve disease, No. (%) | 58 (2.4) | 99 (1.7) | 0.04 |
Medications | Â | Â | Â |
ACE inhibitor use, No. (%) | 596 (24.6) | 800 (13.8) | < 0.0001 |
Beta-blocker use, No. (%) | 743 (30.6) | 1213 (20.9) | < 0.0001 |
- within 72 hours of ETT | 558 (23) | 929 (16) | < 0.0001 |
Statin use, No. (%) | 714 (29.4) | 1213 (20.9) | < 0.0001 |
Calcium channel blocker use, No. (%) | 195 (8) | 214 (3.7) | < 0.0001 |